Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesUrologyAvalon Healthcare Solutions prostate biopsy covera…
    Ask Trek AI about this page
    Currentavalon_healthcare_solutionsPolicy AHS - G2007 - Prostate Biopsy Specimen Analysis

    Prostate Biopsy Specimen Analysis

    Customize your policy alerts

    Sign up for avalon_healthcare_solutions Policy AHS - G2007 - Prostate Biopsy Specimen Analysis alerts

    Get alerted when Policy AHS - G2007 - Prostate Biopsy Specimen Analysis changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing when pathological examination of prostate biopsy tissue is covered or not covered for Avalon Healthcare Solutions members; applies to initial and repeat prostate biopsies and specimen handling for diagnosis and management of prostate cancer.

    Policy Summary
    PayerAvalon Healthcare Solutions
    PolicyProstate Biopsy Specimen Analysis
    Policy CodePolicy AHS - G2007 - Prostate Biopsy Specimen Analysis
    Change TypeNo material clinical or coverage changes
    Effective DateJun 1, 2026
    Last ReviewMar 5, 2026
    Next Review DateJun 1, 2026
    Key ActionSubmit biopsy specimens one vial per sextant (no more than two cores per vial) and document processing to support billing and coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12-corerecommended extended sampling for initial diagnostic biopsy
    up to 24maximum cores described for saturation biopsy
    1 vial = 1 specimenspecimen handling — billing unit
    93%

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    mpMRI sensitivity (PROMIS)
    88305, G0416example procedure codes

    Coverage Criteria

    Covered indications

    Covered when ANY of the following are met:

    Initial diagnosis: Pathological examination of tissue obtained from a prostate biopsy involving 12-core extended sampling as follow-up to abnormal PSA, presence of a palpable nodule on digital rectal examination, or suspicious radiologic findings.12-core extended biopsy

    See Note 1 regarding vial handling

    Repeat biopsy after negative initial biopsy: Pathological examination of tissue from a follow-up prostate biopsy (excluding prostate saturation biopsy) when clinical suspicion of prostate cancer remains after an initial negative biopsy.exclude saturation biopsy

    Repeat biopsy coverage applies when suspicion persists after negative initial biopsy

    Not covered

    The following does not meet coverage criteria:

    Saturation biopsy: Pathological examination of tissue obtained from a prostate saturation biopsy for diagnosis, staging, or management of prostate cancer.saturation biopsy (up to ~24 cores)

    Not covered due to lack of available published scientific literature confirming benefit

    Technique and clinical indications (guideline summary)

    Guideline-based biopsy technique and indications referenced in the policy (clinical rather than payer-authorization criteria):

    Pre-biopsy imaging and sampling: When MRI-targeting capabilities are available, a combination of MRI-targeted and systematic biopsies is preferred, and perform MRI before biopsy when organ-confined disease is suspected.

    Supported by NCCN, EAU, AUA guidance

    Systematic sampling: Use an extended systematic biopsy pattern of at least 12 cores, including apical and far-lateral cores, to improve detection compared with sextant schemes.>=12 cores

    NCCN and AUA recommendations

    MRI-targeted cores per lesion: Obtain at least two needle biopsy cores per MRI-identified target lesion.>=2 cores per target

    AUA guidance

    Pathological examination of prostate saturation biopsy specimens is explicitly excluded from coverage. Tissue obtained via a saturation biopsy does not meet coverage criteria for diagnosis, staging, or management of prostate cancer and may be denied.

    Saturation biopsy is not recommended as a routine strategy for all individuals with prior negative biopsies. NCCN guidance does not support broad use of saturation sampling given the demonstrated benefits of MRI and MRI-targeted biopsy approaches in the repeat-biopsy setting.

    The use of saturation biopsy (extensive sampling up to ~24 cores) for diagnosis, staging, or management is considered not medically necessary and does not meet coverage criteria. Policy limits coverage to established approaches such as extended (≥12-core) systematic sampling and MRI-targeted strategies rather than saturation protocols.

    Per ESMO guidance, when pre-biopsy multiparametric MRI is negative (PI-RADS ≤2) and the clinical suspicion for cancer is low, biopsy may be omitted. This supports a selective, imaging-guided approach to biopsy decision-making rather than routine sampling in low-risk, MRI-negative cases.

    Coding and Billing Guidance

    Applicable CPT/HCPCS Procedure Codesmixed
    88305Level IV - Surgical pathology, gross and microscopic examination.
    G0416Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method
    inv-10: Minimum systematic cores
    Minimum systematic coresAt least 12 cores (extended/12-core systematic sampling)
    PurposeValidated to improve cancer detection compared with sextant schemes
    IncludesApical and far-lateral cores as part of extended pattern
    inv-11: Cores per MRI target
    Cores per MRI-identified targetObtain at least 2 needle biopsy cores per MRI target lesion
    Technique optionsTargets may be sampled via cognitive targeting, TRUS–MRI fusion, or in-bore MRI guidance

    Provider Actions & Operational Notes

    Prior Authorization

    Initial diagnostic 12‑core biopsy — coverage when clinically indicated

    Pathological examination of tissue obtained from a prostate biopsy involving 12-core extended sampling for initial diagnosis (after abnormal PSA, palpable nodule on DRE, or suspicious imaging) meets coverage criteria; authorization depends on the member's benefit plan and Evidence of Coverage.

    Prior Authorization

    Repeat biopsy after negative initial biopsy — coverage when suspicion remains

    Pathological examination of tissue from a follow-up prostate biopsy after an initial negative biopsy meets coverage criteria when clinical suspicion persists; this excludes prostate saturation biopsy.

    Background

    Prostate cancer spans a spectrum from indolent to aggressive disease; elevated PSA, an abnormal digital rectal exam, or suspicious imaging prompts biopsy evaluation. Guidelines favor an imaging-guided approach when available—combining MRI-targeted sampling with systematic cores increases detection of clinically significant cancer. Systematic sampling should use an extended pattern of at least 12 cores, and targeted lesions generally warrant at least 2 cores per MRI-identified target. Saturation biopsy (up to ~24 cores) is associated with higher complication rates and lacks evidence of routine benefit; pathological examination of saturation biopsy tissue is therefore excluded from coverage.

    Definitions

    inv-22: 12-core / extended biopsy
    DefinitionAn extended core biopsy obtaining approximately 12 evenly-distributed specimens including apical and far-lateral cores
    Detection benefit12-core schemes detect substantially more cancers compared with sextant (six-core) approaches
    RangeExtended sampling schemes have been used to obtain up to 18 cores in some protocols
    inv-23: Saturation biopsy
    DefinitionExtensive sampling obtaining up to ~24 core samples
    Appropriate useNot appropriate for initial screening; may be considered after one or more negative TRUS biopsies
    Policy Summary
    PayerAvalon Healthcare Solutions
    PolicyProstate Biopsy Specimen Analysis
    Policy CodePolicy AHS - G2007 - Prostate Biopsy Specimen Analysis
    Change TypeNo material clinical or coverage changes
    Effective DateJun 1, 2026
    Last ReviewMar 5, 2026
    Next Review DateJun 1, 2026
    Key ActionSubmit biopsy specimens one vial per sextant (no more than two cores per vial) and document processing to support billing and coverage.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Billing GuidanceProvider Actions & Operational NotesBackgroundDefinitions
    Biopsy route: Either transrectal or transperineal biopsy routes may be used; transperineal is preferred where available because of lower infection risk.

    AUA and ESMO preference for transperineal

    Repeat biopsy timing: Repeat biopsy (and/or repeat mpMRI) generally not more often than every 12 months unless clinically indicated; most active surveillance patients undergo biopsy every 2–5 years.

    NCCN guidance

    Combined approachCombine targeted sampling with systematic (≥12-core) sampling for higher yield when feasible
    Billing Rule

    Procedure codes listed for reference (88305, G0416)

    Procedure codes 88305 and G0416 are listed for reference only; inclusion in the policy is not a guarantee of payment and prior authorization is not explicitly required in this section.

    • 88305 — Level IV surgical pathology, gross and microscopic examination
    • G0416 — Surgical pathology for prostate needle biopsy, any method
    Step Therapy

    Use mpMRI and targeted (plus systematic) sampling when available

    When available, perform mpMRI and use MRI-targeted biopsy (and consider combined targeted plus systematic sampling) prior to or in conjunction with repeat biopsies; obtain at least two cores per MRI-identified target when targeting lesions.

    • Obtain prostate mpMRI prior to repeat biopsy if no prior MRI exists.
    • Perform targeted biopsies of suspicious MRI lesions and consider concurrent systematic template biopsy.
    • Obtain ≥2 cores per MRI-identified target.
    Documentation Required

    Document clinical indication and biopsy technique to support medical necessity

    Ensure documentation of biopsy technique and clinical indication in the record (e.g., abnormal PSA, DRE findings, suspicious imaging) to support medical necessity for initial and repeat biopsies.

    • Document the clinical indication prompting biopsy (PSA, DRE, imaging).
    • Record whether mpMRI was performed and findings (e.g., PI-RADS) when applicable.
    • Note the sampling pattern (12‑core extended or targeted plus systematic).
    Documentation Required

    Specimen handling — one vial per sextant, ≤2 cores per vial

    Submit biopsy specimens one vial per sextant with no more than two core samples per vial; each vial is considered a single specimen for billing purposes.

    • Label and submit specimens by sextant (one vial per sextant).
    • Limit to ≤2 cores per vial per Note 1 guidance.
    Billing Rule

    Each vial = one billing unit; document labeling and processing

    Billing should treat each vial (one per sextant) as a single specimen regardless of the number of cores in the vial; documentation must support specimen labeling and processing to justify coding (e.g., 88305 or G0416).

    • Ensure pathology request and processing notes reflect vial-level handling.
    • Retain labeling that links each vial to sextant location for audit.
    Denial Risk

    Saturation biopsy specimens — not covered

    Pathological examination of tissue obtained from a prostate saturation biopsy does not meet coverage criteria and may be denied.

    • Saturation biopsy approaches (up to ~24 cores) are excluded from coverage.
    Denial Risk

    Government (LCD/NCD/state) policies take precedence

    If this policy conflicts with an applicable government policy (LCD, NCD, or state Medicaid), the government policy will control and denial determinations will default to that policy.

    • Verify member-specific Medicare or Medicaid coverage via CMS or state Medicaid resources when applicable.
    Risks
    Associated with higher incidence of complications compared with standard sampling
    inv-24: mpMRI
    DefinitionMultiparametric magnetic resonance imaging (mpMRI) of the prostate used for pre-biopsy risk stratification and to guide targeted biopsy
    PI-RADS guidanceWhen mpMRI is negative (PI-RADS ≤2) and clinical suspicion is low, biopsy can be omitted per ESMO
    RoleSupports identification of lesions for MRI-targeted biopsy and aids decision-making prior to biopsy
    inv-25: Extended (12-core) systematic biopsy
    DefinitionAn extended systematic sampling pattern of at least 12 cores including apical and far-lateral cores
    Guideline supportRecommended by NCCN and reaffirmed by AUA for improved detection versus sextant biopsy
    Use caseRecommended for initial diagnostic biopsy and as part of combined systematic plus targeted approaches
    inv-26: MRI-targeted biopsy
    DefinitionImage-guided biopsy targeting lesions identified on pre-biopsy MRI; includes cognitive targeting, TRUS–MRI fusion, or in-bore MRI guidance
    Sampling recommendationObtain at least 2 cores per MRI-identified lesion; combine with systematic sampling when possible for higher sensitivity
    Preferred usePreferred technique when available and recommended by NCCN and AUA guidance